Remember when we bought this company?

Dear Colleagues,


Earlier today, we announced the exciting news that Valeant has agreed to acquire Bausch + Lomb, a leading global eye health company, in an all-cash transaction. This acquisition will create a new growth platform for Valeant with Bausch + Lomb’s strong capabilities in ophthalmic pharmaceuticals, contact lenses and lens care products, and ophthalmic surgical devices and instruments.


Bausch + Lomb’s world-renowned brand, established commercial portfolio of leading eye care products, and promising late-stage pipeline are an ideal strategic fit for Valeant. Importantly, our two companies also share a commitment to providing exceptional service to all of our customers and patients. We have great respect for the people at Bausch + Lomb for building such a strong global company, and we look forward to welcoming them to the Valeant team once the transaction closes.


Valeant’s Ophthalmology and Eye Health business unit will sell products under the iconic Bausch + Lomb name in order to capitalize on the brand recognition and strong reputation in the marketplace. Dan Wechsler, Executive Vice President and President of Bausch + Lomb’s Global Pharmaceuticals, will join Valeant as Executive Vice President and Company Group Chairman, Ophthalmology and Eye Health. Bausch + Lomb’s Chief Medical Officer Calvin W. Roberts, M.D. will also join Valeant as its Chief Medical Officer, Ophthalmology and Eye Health.


Until the acquisition closes, which we expect to be in the third quarter of 2013, we must continue to operate business as usual as separate, independent organizations. In the meantime, we will begin integration planning and expect to share additional details with you in the coming weeks. As with previous transactions, we will make fair and objective decisions in the selection of personnel, and will seek to fill positions with the best candidates available from within both organizations. It is important that we stay focused and not allow this process to distract us from executing our plans and delivering our objectives.


I know you will have many questions, and we are committed to keeping you informed throughout this process.


This is an exciting time for Valeant as we enter a new phase of growth and become a worldwide leader in both dermatology and eye health. My thanks go out to all of you for your many contributions and dedication to helping us build the great company we are today. I look forward to working together to continue our success.


Best regards,


Mike Pearson

 

Yes. & I remember Brian Stolz sending out nasty termination letters to many when we aquired. He will be on the chopping block this time around. I guarantee that!

 

All BS from Mike Pearson! I was a Bausch & Lomb employee and felt so betrayed when we were "sold" to Valeant. Management & Executive at Valeant are the most unprofessional and disgusting people I have ever encountered. The employee are decent but take on nasty qualities if they work for Valeant too long. Valeant manager and execs that came to Bausch & Lomb were absolutely awful. The VP of HR, Brigitte is a two faced B*$@# who delights in terminating employees. She needs to take lessons from the former HR team at Bausch & Lomb.

 

Now it's time to sell, Ackman!
http://theshadowbanker.org/2016/01/11/letter-bill-ackman/

 

Don't sweat it. It's just the way pharma people are in Jersey.